A typical clinical and pharmacological article
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Human Ig, replenishing the deficit of antibodies, reduces the risk of infections in patients with primary and secondary immunodeficiency.
INDICATIONS
Congenital immunodeficiency conditions (congenital complete or partial immunodeficiency, variational immunodeficiency, severe combined immunodeficiency, Wiskott-Aldrich syndrome); idiopathic thrombocytopenic purpura (especially acute forms in children).
Acquired immunodeficiency (chronic lymphocytic leukemia, AIDS in children, bone marrow transplantation and other types of transplantation); Kawasaki syndrome (as an adjunct to acetylsalicylic acid therapy); prevention and treatment of infectious diseases.
DOSING MODE
In / in the drip. Before administration, the drug should be warmed to room temperature or body temperature. You can enter only a clear solution.
The initial infusion rate is 30 cap / min (1.65 ml / min), after 10 min the rate is increased to 40 cap / min (2.2 ml / min).
Substitution therapy for primary and secondary immunodeficiencies (including children with AIDS): 0.1-0.4 g / kg at intervals of 1 month until the level of IgG increases. In the absence of a sufficient increase in IgG levels or an excessively rapid decrease in the index, the dose is increased to 0.8 g / kg or the intervals between administrations are shortened.
Idiopathic thrombocytopenic purpura is 0.8-1 g / kg (if necessary, repeat for 2 or 3 days) or 0.4 g / kg for 2-5 days. If necessary, repeat the course.
Allogeneic bone marrow transplantation - 0.5 g / kg for 7 days.
Kawasaki syndrome - 1.6-2 g / kg in several doses (for 2-5 days) or 2 g / kg in a single dose.
In severe bacterial infections (including sepsis) and viral infections - 0.4-1 g / kg daily for 1-4 days.
To prevent infections in premature infants with a low birth weight - 0.5-1 g / kg with an interval of 1-2 weeks.
With Guillain-Barre syndrome, chronic inflammatory demyelinating neuropathy - 0.4 g / kg for 5 days. If necessary, the course of treatment is repeated at intervals of 4 weeks.
In patients with ischemic heart disease and cerebral ischemia, 0.4 g / kg is administered daily.
SIDE EFFECT
Headache, chills, fever, nausea, vomiting, aches in joints, back pain, allergic reactions.
Rarely, a decrease in blood pressure, in a few cases - anaphylactic shock, symptoms of aseptic meningitis (severe headache, nausea, vomiting, fever, stiff neck, photosensitivity, impaired consciousness), aggravation of kidney failure in patients with impaired renal function.
CONTRAINDICATIONS
Hypersensitivity, IgA deficiency against the background of the patient's antibodies against IgA.
With caution: pregnancy, lactation.
PREGNANCY AND LACTATION
With caution: pregnancy, lactation.
APPLICATION FOR CHILDREN
The use is possible according to the indications and in accordance with the dosing regimen.
SPECIAL INSTRUCTIONS
A temporary increase in the amount of injected antibodies in the patient's blood after Ig administration may result in false positive serological test results.
Do not exceed the recommended rate of drug administration (probably the development of serious side effects). During the entire infusion period and 20 minutes after it, the patient should be under medical supervision.
DRUG INTERACTION
Reduces the activity of weakened live measles, rubella, mumps, varicella vaccines (when administered within the first 2 weeks after vaccination against measles, mumps and rubella vaccination, these vaccines should be repeated no earlier than 3 months).
You can mix only with 0.9% solution of sodium chloride. Other drugs can not be added to the solution. a change in the electrolyte concentration or the pH value can cause denaturation or precipitation of the protein.
